We develop a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections.
Serine ß-lactamase Inhibitor (SBLi)
We develop a novel serine ß-lactamase inhibitor with excellent coverage against KPC superbugs and best in class potential vs OXA producers including Acinetobacter.
Pseudomonas Elastase Inhibitors (PEi)
A program powered by CARB-X seeking to develop a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the treatment of chronic respiratory infections in Cystic Fibrosis patients.
WHAT WE DO
We are a private biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO.